BLU-U is designed to deliver a uniform light dose and stable wavelength to an entire treatment area1
- The large U-shaped design and tube spacing:
- allows for the treatment of an entire face or scalp
- delivers consistent light dose all the way to the treatment "edges"
- The BLU-U is designed with a reflective wall behind the tubes to minimize loss of light within the U-shaped treatment area
- Light tubes are spaced much closer together at the top and bottom than in the middle to compensate for light falloff in this area
BLU-U is designed to deliver a consistent light dose1
- The phosphor in the fluorescent tubes produces a very stable and cost-effective wavelength
- The BLU-U contains a microprocessor that continuously monitors and adjusts light output to maintain dose stability from the first to the last treatment
- BLU-U does not emit UVA or UVB light
- The unique design of the BLU-U was developed to mitigate potential light dose variations caused by the effects of "the inverse square law".
- For example, if you have a skin area 2 inches from a light source and the patient moves so that the area is now 4 inches from the light source, the skin area will receive only 1/4 of that light exposure that it would have at 2 inches.
- However, due to the unique U-shaped design of the BLU-U and the use of specially shaped internal reflectors, a patient in a similar circumstance as described above would not be subjected to the same reduction in light exposure.
To view a more detailed presentation on the BLU-U technology please click here.
Use with eyewear that blocks light of at least 500 nm and shorter with an optical density of two or greater.
Indication
Levulan® Kerastick® (aminolevulinic acid HCl) for Topical Solution, 20% plus blue light illumination using the BLU-U® Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
Important Risk Information
Application of Levulan® Kerastick® should involve either scalp or face lesions, but not both simultaneously. Levulan® Kerastick® should not be applied to the periorbital area or allowed to contact ocular or mucosal surfaces. Excessive irritation may be experienced if this product is applied under occlusion.
Contraindicated in patients with cutaneous photosensitivity at wavelengths of 400-450 nm, porphyria, or known allergies to porphyrins, and in patients with known sensitivity to any of the components of the Levulan Kerastick for Topical Solution.
Levulan® Kerastick® has not been tested on patients with inherited or acquired coagulation defects. It is possible that concomitant use of other known photosensitizing agents might increase the photosensitivity reaction of actinic keratoses treated with the Levulan® Kerastick®.
Patients should avoid exposure of the photosensitive treatment sites to sunlight or prolonged or intense light for at least 40 hours after application of the Levulan Kerastick Topical Solution. Exposure may result in a stinging and/or burning sensation and may cause erythema or edema of the lesions. Patients should protect treated lesions from the sun by wearing a wide-brimmed hat or similar head covering of light-opaque material. Sunscreens will not protect against photosensitivity reactions caused by visible light.
Most common adverse events including stinging and/or burning, itching, erythema, and edema were observed in all clinical studies. Severe stinging and/or burning at one or more lesions being treated was reported by at least 50% of patients at some time during treatment. However, less than 3% of patients discontinued light treatment due to stinging and/or burning.
During light treatment, both patients and medical personnel should be provided with blue blocking protective eyewear, as specified in the BLU-U operating instructions to minimize ocular exposure.
For additional important safety information, please see full prescribing information.
- Data on file, DUSA Pharmaceuticals, Inc.®
